Title:
REDUCED FLUENCE RATE PDT
Document Type and Number:
WIPO Patent Application WO2002062384
Kind Code:
A3
Abstract:
The invention relates to the use of reduced fluence rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluence rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.
More Like This:
Inventors:
STRONG H ANDREW
Application Number:
PCT/CA2002/000135
Publication Date:
May 15, 2003
Filing Date:
February 06, 2002
Export Citation:
Assignee:
QUADRA LOGIC TECH INC (CA)
International Classes:
A61K41/00; A61N5/06; (IPC1-7): A61K41/00
Domestic Patent References:
| WO1995024930A1 | 1995-09-21 | |||
| WO2001035996A2 | 2001-05-25 | |||
| WO2002062386A2 | 2002-08-15 |
Foreign References:
| US20010023247A1 | 2001-09-20 |
Other References:
FOSTER, THOMAS H. ET AL: "Analysis of photochemical oxygen consumption effects in photodynamic therapy", PROCEEDINGS OF SPIE-THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (1992), 1645(PROC. OPT. METHODS TUMOR TREAT. DETECT.: MECH. TECH. PHOTODYN. THER., 1992), 104-14, XP008013788
HENDERSON B W ET AL: "Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.", CANCER RESEARCH. UNITED STATES 1 FEB 2000, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 525 - 529, XP002231035, ISSN: 0008-5472
HENDERSON B W ET AL: "Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate.", CANCER RESEARCH. UNITED STATES 1 FEB 2000, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 525 - 529, XP002231035, ISSN: 0008-5472
Download PDF: